Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00923884 · ClinicalTrials.gov registry record

Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer

A clinical trial, sponsored by National Cancer Institute (NCI).

Completed
Registry status
546
Enrollment target

NCT00923884: Completed study, sponsored by National Cancer Institute (NCI).

NCT00923884 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 546 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00923884 has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
546 participants
Enrollment target

Study Summary

Background: * The Lung Cancer section of the National Cancer Institute s Medical Oncology Branch is running a study to better understand which genes might be important in patients who are undergoing therapy for lung cancer. Objectives: * To find out if differences (also called polymorphisms) in specific genes lead to differences in outcomes (such as treatment success and survival rates) for patients who have been diagnosed with lung cancer. * To establish a repository of genetic information for future studies of these differences and their relation to lung cancer. Eligibility: * Any individual who has been diagnosed with lung cancer and is being treated through the National Cancer Institute. Design: * After entrance in this study, patients will provide information to the researchers on age, gender, race/ethnicity, treatments received and response to treatments, and other specific information about their disease. This information will be kept confidential. * Approximately half a tablespoon of blood will be drawn. * Patients will be treated for lung cancer with normal treatment methods, as if they had not been enrolled in the study * Some patients may be offered the option of enrolling in separate research protocols for cancer treatment, involving chemotherapy, surgery, or radiation.

Trial Details

FieldValue
Enrollment Target 546 participants
Start Date 2009-03-18
Est. Completion 2018-04-20

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT00923884

The ClinicalTrials.gov registry entry for NCT00923884 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 546 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT00923884 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00923884 about?

NCT00923884 is a clinical study titled "Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer". Background: * The Lung Cancer section of the National Cancer Institute s Medical Oncology Branch is running a study to better understand which genes might be important in patients who are undergoing therapy for lung cancer. Objectives: * To find out if differences (also called polymorphisms) in s...

What is the current status of trial NCT00923884?

This trial is currently completed. The enrollment target is 546 participants. The study started on 2009-03-18. Estimated completion is 2018-04-20.

Who is sponsoring clinical trial NCT00923884?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.